

Contents

Introduction	1
Introduction	3
<i>J.M. Wood</i>	
 <i>Session I</i>	
Isolation and Cultivation of Influenza Virus on Mammalian Cells	5
Chairperson: <i>G.C. Schild</i>	
An Overview of Host Cell Selection	7
<i>J.S. Robertson</i>	
Suitability of MDCK Cells Grown in a Serum-Free Medium for Influenza Virus Production	13
<i>N. Kessler, G. Thomas-Roche, L. Gérentes, M. Aymard</i>	
Production of Influenza Virus in Serum-Free Mammalian Cell Cultures	23
<i>O-W Merten, J.C. Manuguerra, C. Hannoun, S. van der Werf</i>	
Growth and Immunogenicity of Influenza Viruses Cultivated in Vero or MDCK Cells and in Embryonated Chicken Eggs	39
<i>E.A. Govorkova, S. Kodihalli, I.V. Alymova, B. Fanget, R.G. Webster</i>	
Evaluation of Immune Responses to Inactivated Influenza Vaccines Prepared in Embryonated Chicken Eggs and MDCK Cells in a Mouse Model	53
<i>K. Nerome, H. Kumihashi, R. Nerome, Y. Hiromoto, Y. Yokota, R. Ueda, K. Omoe, M. Chiba</i>	
Cell Culture for Surveillance of Influenza	65
<i>M. Zambon</i>	
Discussion	73
 <i>Session II</i>	
Selection of Vaccine Strains	75
Chairperson: <i>P.D. Minor</i>	
Generation and Characterisation of Reassortant Influenza A Viruses Propagated in Serum-Free Cultured MDCK-SF1 Cells	77
<i>J.T.M. Voeten, E.C.J. Claas, R. Brands, A.M. Palache, G.J.M. van Scharrenburg, G.F. Rimmelzwaan, A.D.M.E. Osterhaus</i>	
Discussion	89

Session III

Scale up for Vaccine Production	91
Chairperson: <i>I. Furminger</i>	
Influvac ^{TC} : A Safe Madin Darby Canine Kidney (MDCK) Cell Culture Based Influenza Vaccine <i>R. Brands, J. Visser, J. Medema, A.M. Palache, G.J.M. van Scharrenburg</i>	93
Development of a Vero Cell-Derived Influenza Whole Virus Vaccine	101
<i>O. Kistner, P.N. Barrett, W. Mundt, M. Reiter, S. Schober-Bendixen, G. Eder, F. Dörner</i>	
Discussion	111

Session IV

Clinical Trials	113
Chairperson: <i>K. Nicholson</i>	
Safety, Reactogenicity and Immunogenicity of Madin Darby Canine Kidney Cell-Derived Inactivated Influenza Subunit Vaccine. A Meta-Analysis of Clinical Studies	115
<i>A.M. Palache, H.S.J. Scheepers, V. de Regt, P. van Ewijk, M. Baljet, R. Brands, G.J.M. van Scharrenburg</i>	
A Phase I, Randomised Controlled Clinical Trial to Study the Reactogenicity and Immuno- genicity of a New Split Influenza Vaccine Derived from a Non-Tumorigenic Cell Line	127
<i>P.B. Percheson, P. Trépanier, R. Dugré, T. Mabrouk</i>	
Discussion	133

Session V

General Regulatory Issues (1): Cell Substrates	135
Chairperson: <i>E. Griffiths</i>	
Experience with Vero Cell at Pasteur Mérieux Connaught	137
<i>B.J. Montagnon, J.C. Vincent-Falquet, J.F. Saluzzo</i>	
Quality Assurance for Cell Substrates	141
<i>G.N. Stacey, P. Phillips</i>	
WHO Requirements for the Use of Animal Cells as In Vitro Substrates for the Production of Biologicals: Application to Influenza Vaccine Production	153
<i>E. Griffiths</i>	
ICH Guidelines and PhEur Monographs on Derivation and Characterisation of Cell Sub- strates Used for Production of Biotechnological/Biological Products	159
<i>R. Dobbelaer</i>	
Discussion	167

Session VI

General Regulatory Issues (2): Cell Culture Influenza Vaccines	169
Chairperson: <i>R.A. Levandowski</i>	
Regulatory Perspective in the United States on Cell Cultures for Production of Inactivated Influenza Virus Vaccines	171
<i>R.A. Levandowski</i>	

Cell Culture Influenza Vaccine: An Australian Perspective	177
<i>L. Chang, R. Crichton, P. Nandapalan</i>	
The Influence of the Host Cell on Standardisation of Influenza Vaccine Potency	183
<i>J.M. Wood, U. Dunleavy, R.W. Newman, A.-M. Riley, J.S. Robertson, P.D. Minor</i>	
Difficulties in Standardizing the Neuraminidase Content of Influenza Vaccines	189
<i>L. Gérentes, N. Kessler, M. Aymard</i>	
Discussion	197
 <i>Session VII</i>	
Summary and Recommendations	199
Summary and Recommendations	201
<i>P.D. Minor</i>	